903 related articles for article (PubMed ID: 34781162)
1. Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups.
Ferri C; Ursini F; Gragnani L; Raimondo V; Giuggioli D; Foti R; Caminiti M; Olivo D; Cuomo G; Visentini M; Cacciapaglia F; Pellegrini R; Pigatto E; Urraro T; Naclerio C; Tavoni A; Puccetti L; Varcasia G; Cavazzana I; L'Andolina M; Ruscitti P; Vadacca M; Gigliotti P; La Gualana F; Cozzi F; Spinella A; Visalli E; Dal Bosco Y; Amato G; Masini F; Pagano Mariano G; Brittelli R; Aiello V; Caminiti R; Scorpiniti D; Rechichi G; Ferrari T; Monti M; Elia G; Franceschini F; Meliconi R; Casato M; Iannone F; Giacomelli R; Fallahi P; Santini SA; Zignego AL; Antonelli A
J Autoimmun; 2021 Dec; 125():102744. PubMed ID: 34781162
[TBL] [Abstract][Full Text] [Related]
2. Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases.
Ferri C; Gragnani L; Raimondo V; Visentini M; Giuggioli D; Lorini S; Foti R; Cacciapaglia F; Caminiti M; Olivo D; Cuomo G; Pellegrini R; Pigatto E; Urraro T; Naclerio C; Tavoni A; Puccetti L; Cavazzana I; Ruscitti P; Vadacca M; La Gualana F; Cozzi F; Spinella A; Visalli E; Bosco YD; Amato G; Masini F; Mariano GP; Brittelli R; Aiello V; Scorpiniti D; Rechichi G; Varcasia G; Monti M; Elia G; Franceschini F; Casato M; Ursini F; Giacomelli R; Fallahi P; Santini SA; Iannone F; Salvarani C; Zignego AL; Antonelli A
J Autoimmun; 2022 Jul; 131():102866. PubMed ID: 35841684
[TBL] [Abstract][Full Text] [Related]
3. A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases.
Tzioufas AG; Bakasis AD; Goules AV; Bitzogli K; Cinoku II; Chatzis LG; Argyropoulou OD; Venetsanopoulou AI; Mavrommati M; Stergiou IE; Pezoulas V; Voulgari PV; Katsimpari C; Katechis S; Gazi S; Katsifis G; Sfontouris CI; Georgountzos AI; Liossis SN; Papagoras C; Fotiadis DI; Skopouli FN; Vlachoyiannopoulos PG; Moutsopoulos HM
J Autoimmun; 2021 Dec; 125():102743. PubMed ID: 34757289
[TBL] [Abstract][Full Text] [Related]
4. Risk of disease flares after SARS-CoV-2 mRNA vaccination in patients with systemic lupus erythematosus.
Kikuchi J; Kondo Y; Kojima S; Kasai S; Sakai Y; Takeshita M; Hiramoto K; Saito S; Fukui H; Hanaoka H; Suzuki K; Kaneko Y
Immunol Med; 2024 Jun; 47(2):76-84. PubMed ID: 38189429
[TBL] [Abstract][Full Text] [Related]
5. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.
Furer V; Eviatar T; Zisman D; Peleg H; Paran D; Levartovsky D; Zisapel M; Elalouf O; Kaufman I; Meidan R; Broyde A; Polachek A; Wollman J; Litinsky I; Meridor K; Nochomovitz H; Silberman A; Rosenberg D; Feld J; Haddad A; Gazzit T; Elias M; Higazi N; Kharouf F; Shefer G; Sharon O; Pel S; Nevo S; Elkayam O
Ann Rheum Dis; 2021 Oct; 80(10):1330-1338. PubMed ID: 34127481
[TBL] [Abstract][Full Text] [Related]
7. Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination.
Ali H; Alterki A; Sindhu S; Alahmad B; Hammad M; Al-Sabah S; Alghounaim M; Jamal MH; Aldei A; Mairza MJ; Husain M; Deverajan S; Ahmad R; Cherian P; Alkhairi I; Alkandari A; Abubaker J; Abu-Farha M; Al-Mulla F
Front Immunol; 2021; 12():752233. PubMed ID: 34899701
[TBL] [Abstract][Full Text] [Related]
8. Real-World Effectiveness and Immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis.
Sibbel S; McKeon K; Luo J; Wendt K; Walker AG; Kelley T; Lazar R; Zywno ML; Connaire JJ; Tentori F; Young A; Brunelli SM
J Am Soc Nephrol; 2022 Jan; 33(1):49-57. PubMed ID: 34789546
[TBL] [Abstract][Full Text] [Related]
9. 18-month longitudinal SARS COV-2 neutralizing antibody dynamics in haemodialysis patients receiving heterologous 3-dose vaccination (AZD-1222- AZD-1222- BNT162b2) in a lower middle income setting.
Karunathilake RP; Kumara RA; Karunathilaka A; Wazil AWM; Nanayakkara N; Bandara CK; Abeysekera RA; Noordeen F; Gawarammana IB; Ratnatunga CN
BMC Nephrol; 2024 May; 25(1):176. PubMed ID: 38778281
[TBL] [Abstract][Full Text] [Related]
10. BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus.
Moyon Q; Sterlin D; Miyara M; Anna F; Mathian A; Lhote R; Ghillani-Dalbin P; Breillat P; Mudumba S; de Alba S; Cohen-Aubart F; Haroche J; Pha M; Boutin THD; Chaieb H; Flores PM; Charneau P; Gorochov G; Amoura Z
Ann Rheum Dis; 2022 Apr; 81(4):575-583. PubMed ID: 34607791
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.
Markewitz R; Juhl D; Pauli D; Görg S; Junker R; Rupp J; Engel S; Steinhagen K; Herbst V; Zapf D; Krüger C; Brockmann C; Leypoldt F; Dargvainiene J; Schomburg B; Sharifzadeh S; Nejad LS; Wandinger KP; Ziemann M
Front Immunol; 2022; 13():811020. PubMed ID: 35126395
[TBL] [Abstract][Full Text] [Related]
12. Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis.
Pellicano C; Campagna R; Oliva A; Leodori G; Miglionico M; Colalillo A; Mezzaroma I; Mastroianni CM; Turriziani O; Rosato E
Clin Rheumatol; 2022 Sep; 41(9):2755-2763. PubMed ID: 35614287
[TBL] [Abstract][Full Text] [Related]
13. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
Front Immunol; 2021; 12():704773. PubMed ID: 34220867
[TBL] [Abstract][Full Text] [Related]
14. Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-naïve and Experienced Individuals.
Uprichard SL; O'Brien A; Evdokimova M; Rowe CL; Joyce C; Hackbart M; Cruz-Pulido YE; Cohen CA; Rock ML; Dye JM; Kuehnert P; Ricks KM; Casper M; Linhart L; Anderson K; Kirk L; Maggiore JA; Herbert AS; Clark NM; Reid GE; Baker SC
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215962
[TBL] [Abstract][Full Text] [Related]
15. Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases.
Bakasis AD; Bitzogli K; Mouziouras D; Pouliakis A; Roumpoutsou M; Goules AV; Androutsakos T
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215801
[TBL] [Abstract][Full Text] [Related]
16. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
[TBL] [Abstract][Full Text] [Related]
17. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial.
Oosting SF; van der Veldt AAM; GeurtsvanKessel CH; Fehrmann RSN; van Binnendijk RS; Dingemans AC; Smit EF; Hiltermann TJN; den Hartog G; Jalving M; Westphal TT; Bhattacharya A; van der Heiden M; Rimmelzwaan GF; Kvistborg P; Blank CU; Koopmans MPG; Huckriede ALW; van Els CACM; Rots NY; van Baarle D; Haanen JBAG; de Vries EGE
Lancet Oncol; 2021 Dec; 22(12):1681-1691. PubMed ID: 34767759
[TBL] [Abstract][Full Text] [Related]
18. Predictors of a weak antibody response to COVID-19 mRNA vaccine in systemic lupus erythematosus.
Parsons C; Rubio J; Boulougoura A; Krishfield S; Kyttaris V
Rheumatol Int; 2023 Sep; 43(9):1621-1627. PubMed ID: 37310438
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS-CoV-2 Vaccination.
Izmirly PM; Kim MY; Samanovic M; Fernandez-Ruiz R; Ohana S; Deonaraine KK; Engel AJ; Masson M; Xie X; Cornelius AR; Herati RS; Haberman RH; Scher JU; Guttmann A; Blank RB; Plotz B; Haj-Ali M; Banbury B; Stream S; Hasan G; Ho G; Rackoff P; Blazer AD; Tseng CE; Belmont HM; Saxena A; Mulligan MJ; Clancy RM; Buyon JP
Arthritis Rheumatol; 2022 Feb; 74(2):284-294. PubMed ID: 34347939
[TBL] [Abstract][Full Text] [Related]
20. Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment.
Amatu A; Pani A; Patelli G; Gagliardi OM; Loparco M; Piscazzi D; Cassingena A; Tosi F; Ghezzi S; Campisi D; Grifantini R; Abrignani S; Siena S; Scaglione F; Sartore-Bianchi A
Eur J Cancer; 2022 Mar; 163():16-25. PubMed ID: 35032813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
